Acorda again submits Fampridine-SR for U.S. approval

04/23/2009 | Reuters

Acorda Therapeutics resubmitted its multiple sclerosis drug Fampridine-SR for FDA approval a month after the agency rejected the application because of "format issues." Analysts expect the agency to accept the filing by late June and hand down a decision in February.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC